On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

Sunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBC: Fort Lauderdale, Florida Monday, November 25, 2024, 15:00 Hrs [IST] S ...

The authors suggested this could be linked to chronic inflammation and damage to small bile ducts in the liver, leading to altered adiponectin metabolism. Read more about PBC testing “This finding ...

Patients whose ATX levels were above the threshold had a cumulative liver-related events incidence of 33.3% Novel biomarkers could help predict disease progression for patients with primary biliary ...

PBC is the most frequent CD-related liver disease, being regarded as the most prevalent autoimmune disorder detected in CD after Hashimoto thyroiditis, Type 1 diabetes mellitus and Sjogren syndrome.

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications ...

GSK plc announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter ...

Aug. 21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease. This exotic fruit reduces liver fat ... Liver Transplant Outperforms Other Therapies for ...